A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-Month follow-up results of the EXCELLA II study

EuroIntervention

Volumn 6, Issue 2, 2010, Pages 195-205

  Serruys, Patrick W ^a   Garg, Scot ^a   Abizaid, Alexandre ^b   Ormiston, John ^c   Windecker, Stephan ^d   Verheye, Stefan ^e   Dubois, Christophe ^f   Stewart, Jim ^c   Hauptmann, Karl E ^g   Schofer, Joachim ^h   Stangl, Karl ⁱ   Witzenbichler, Bernhard ⁱ   Wiemer, Marcus ^j   Barbato, Emanuele ^k   De Vries, Ton ^l   Den Drijver, Anne Marie ^l   Otake, Hiromasa ^m   Meredith, Lynn ⁿ   Toyloy, Sara ^m   Fitzgerald, Peter ^m  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^c Mercy Angiography Unit   (New Zealand)

^d UNIVERSITY OF BERN   (Switzerland)

^e MIDDELHEIM HOSPITAL   (Belgium)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Germany)

^h UNIVERSITY HEART CENTER HAMBURG   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j RUHR UNIVERSITY BOCHUM   (Germany)

^k OLV HOSPITAL   (Belgium)

^l CARDIALYSIS   (Netherlands)

^m STANFORD UNIVERSITY   (United States)

ⁿ Elixir Medical   (United States)

more..

Author keywords

Angioplasty; Novolimus eluting stent; Zotarolimus eluting stent

Indexed keywords

MACROLIDE; NOVOLIMUS; POLY N BUTYL METHACRYLATE; POLYMER; UNCLASSIFIED DRUG; ZOTAROLIMUS; DRUG DERIVATIVE; RAPAMYCIN;

ADULT; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; TIME;

CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MACROLIDES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SIROLIMUS; TIME FACTORS;

EID: 77956148513     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV6I2A32     Document Type: Article

References (34)

1. Garg S, Serruys PW. Coronary stents - Current Status. J Am Coll Cardiol. In Press.
2. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780. (Pubitemid 34586912)
3. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788-794. (Pubitemid 37022118)
4. Serruys PW, Ong AT, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher A, Grube E, Haase J, Thuesen L, Hamm C, Otto-Terlouw PC. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention. 2005;1:58-65.
5. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006;114:798-806. (Pubitemid 44268230)
6. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937-948. (Pubitemid 47393576)
7. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L, the SSG. Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in Sweden. N Engl J Med. 2007;356:1009-1019. (Pubitemid 46376801)
8. Schomig A, Dibra A, Windecker S, Mehilli J, Suarez de Lezo J, Kaiser C, Park SJ, Goy JJ, Lee JH, Di Lorenzo E, Wu J, Juni P, Pfisterer ME, Meier B, Kastrati A. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1373-1380. (Pubitemid 47449734)
9. Costa JR, Jr., Abizaid A, Feres F, Costa R, Seixas AC, Maia F, Tanajura LF, Staico R, Siqueira D, Meredith L, Bhat V, Yan J, Ormiston J, Sousa AG, Fitzgerald P, Sousa JE. EXCELLA First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions. EuroIntervention. 2008;4:53-58.
10. Abizaid A, Costa JR Jr., Feres F, Costa R, Seixas A, Maia F, Staico R, Siqueira D, Ormiston J, Sousa AGMR, Fitzgerald P, Honda Y, Otake H, Sousa JE. TCT-429: Single Center, First-In-Man Study of the Elixir Novolimus Eluting Coronary Stent System with Durable Polymer 24-Month Clinical Safety and Efficacy Results. Am J Cardiol. 2009;104:158D-158D.
11. Serruys PW, Foley D, De Feyter PJ, eds. Quantitative coronary angiography in clinical practice. Dordrecht, The Netherlands, 1994.
12. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351. (Pubitemid 46685903)
13. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation. 1979;59:607-609.
14. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR, Jr., Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996;94:1690-1697. (Pubitemid 26320276)
15. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202. (Pubitemid 43929240)
16. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701-705. (Pubitemid 38222887)
17. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, Yarnold PR, Belknap SM, West DP, Gage JE, Morse RE, Gligoric G, Davidson L, Feldman MD. Hypersensitivity Cases Associated With Drug-Eluting Coronary Stents: A Review of Available Cases From the Research on Adverse Drug Events and Reports (RADAR) Project. J Am Coll Cardiol. 2006;47:175-181. (Pubitemid 43005183)
18. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333-342. (Pubitemid 352001347)
19. Tsuchida K, Garcia-Garcia HM, Ong AT, Valgimigli M, Aoki J, Rademaker TA, Morel MA, van Es GA, Bruining N, Serruys PW. Revisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: analysis from the SPIRIT FIRST trial. Catheter Cardiovasc Interv. 2006;67:188-197. (Pubitemid 43235149)
20. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J. 2007;28:2525-2538. (Pubitemid 47616190)
21. Eisenstein EL, Leon MB, Kandzari DE, Mauri L, Edwards R, Kong DF, Cowper PA, Anstrom KJ, for the EIIII. Long-term clnical and economic analysis of the Endeavor Zotarolimus-eluting stent versus the Cypher Sirolimus-eluting stent: 3-year results from the ENDEAVOR III Trial (randomized controlled trial of the Medtronic Endeavor drug [ABT-578] eluting coronary stent system versus the Cypher Sirolimus-eluting coronary stent system in de novo native coronary artery lesions). J Am Coll Cardiol Intv. 2009;2:1199-1207.
22. Leon MB, Mauri L, Popma JJ, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, McLaurin BT, Solomon SL, Douglas Jr JS, Ball MW, Caputo RP, Jain A, Tolleson TR, Reen Iii BM, Kirtane AJ, Fitzgerald PJ, Thompson K, Kandzari DE. A randomised comparison of the Endeavor Zotarolimus-eluting stent versus the TAXUS Paclitaxel-eluting stent in de novo native coronary lesions: 12-Month outcomes from the ENDEAVOR IV Trial. J Am Coll Cardiol. 2010;55:543-554.
23. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375:201-209.
24. Vranckx P, Cutlip D, Mehran R, Kint P-P, Silber S, Windecker S, Serruys PW. Myocardial Infarction adjudication in Contemporary All-Comer Stent trials: Balancing sensitivity and specificity. EuroIntervention. 2010;5:871-874.
25. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
26. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J. 2006;27:2784-2814. (Pubitemid 44871464)
27. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007;115:1440-1455; discussion 1455.
28. Rasmussen K, Maeng M, Kaltoft A, Thayssen P, Kelbaek H, Tilsted HH, Abildgaard U, Christiansen EH, Engstrom T, Krusell LR, Ravkilde J, Hansen PR, Hansen KN, Abildstrom SZ, Aaroe J, Jensen JS, Kristensen SD, Botker HE, Madsen M, Johnsen SP, Jensen LO, Sorensen HT, Theusen L, Lassen JF. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet. 2010;375:1090-1099.
29. Hamm C. 5 years later and more than 20,000 patients studied: the ENDEAVOR clinical programme. EuroPCR 19th-22nd May 2009; Barcelona [online] Available: www.europcronline.com/fo/lecture/view-slide.php?idCongres=5&id=7617 [Accessed 20th June 2009].
30. Camenzind E, Wijns W, Mauri L, Boersma E, Parikh K, Kurowski V, Gao R, Bode C, Greenwood JP, Gershlick A, O'Neill W, Serruys PW, Jorissen B, Steg PG. Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. Am Heart J. 2009;158:902-909 e905.
31. Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, Turco M, Applegate RJ, Gurbel PA, Midei MG, Badre SS, Mauri L, Thompson KP, LeNarz LA, Kuntz RE. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006;48:2440-2447. (Pubitemid 44881222)
32. Leon M. The ENDEAVOR and ENDEAVOR Resolute Zotarolimus-Eluting Stent: Comprehensive Update of the Clinical Trial Program (Featuring the First Presentation of the ENDEAVOR IV 3-Year Results). Presentation at Transcatheter Cardiovascular Therapeutics, San Francisco, 21st September 2009. Available online: www.tctmd.com/txshow.aspx?tid=939082&id=84004&trid=938634. [Accessed October 28th 2009].
33. Raber L. SIRTAX-LATE: Five-Year Clinical and Angiographic Follow-up from a Prospective Randomized Trial of Sirolimus-Eluting and Paclitaxel-Eluting Stents. Presentation Transcatheter Cardiovascular Therapeutics, San Francisco, 22nd September 2009.
34. Claessen BE, Beijk MA, Legrand V, Ruzyllo W, Manari A, Varenne O, Suttorp MJ, Tijssen JGP, Miquel-Hebert K, Veldhof S, Henriques JPS, Serruys PW, Piek JJ. Two-Year Clinical, Angiographic, and Intravascular Ultrasound Follow-Up of the XIENCE V Everolimus-Eluting Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions: The SPIRIT II Trial. Circ Cardiovasc Intervent. 2009;2:339-347.